Composite of plasma pharmacokinetics (PK) parameters of afuresertib, following administration with and without food PK samples will be collected at Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, and 72 hours post-dose in each dosing period [clinicaltrials_resource:4a03d7c7ec9a3bcf14a4ba6c22e2f0e1]

Composite of plasma pharmacokinetics (PK) parameters of afuresertib, following administration with and without food PK samples will be collected at Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, and 72 hours post-dose in each dosing period [clinicaltrials_resource:4a03d7c7ec9a3bcf14a4ba6c22e2f0e1]

Relative bioavailability of afuresertib after single dose of a GC, HPMC capsule and ECT, with and without high fat/calorie meal, will be determined by the following PK parameters: Area under the plasma concentration time curve- from time zero (pre-dose) to infinite time [AUC(0-inf)] and from time zero (pre-dose) to last time of quantifiable concentration [AUC(0-t)], maximum observed plasma concentration (Cmax), time to Cmax (tmax), observed plasma concentration at 24 hours (C24), and minimal observed plasma concentration (Ct)
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Primary outcome [clinicaltrials_vocabulary:primary-outcome]
http://bio2rdf.org/clinicaltrials_resource:4a03d7c7ec9a3bcf14a4ba6c22e2f0e1
Bioavailability and Food Effect of the Original Gelatin Formulation and Two New Formulations of Afuresertib in Normal Healthy Volunteers [clinicaltrials:NCT01827644]
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Composite of plasma pharmacokinetics (PK) parameters of afuresertib, following administration with and without food PK samples will be collected at Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, and 72 hours post-dose in each dosing period [clinicaltrials_resource:4a03d7c7ec9a3bcf14a4ba6c22e2f0e1]

Relative bioavailability of afuresertib after single dose of a GC, HPMC capsule and ECT, with and without high fat/calorie meal, will be determined by the following PK parameters: Area under the plasma concentration time curve- from time zero (pre-dose) to infinite time [AUC(0-inf)] and from time zero (pre-dose) to last time of quantifiable concentration [AUC(0-t)], maximum observed plasma concentration (Cmax), time to Cmax (tmax), observed plasma concentration at 24 hours (C24), and minimal observed plasma concentration (Ct)
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Primary outcome [clinicaltrials_vocabulary:primary-outcome]
http://bio2rdf.org/clinicaltrials_resource:4a03d7c7ec9a3bcf14a4ba6c22e2f0e1
Bio2RDF identifier
4a03d7c7ec9a3bcf14a4ba6c22e2f0e1
Bio2RDF namespace
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:4a03d7c7ec9a3bcf14a4ba6c22e2f0e1
measure [clinicaltrials_vocabulary:measure]
Composite of plasma pharmacoki ...... stration with and without food
time frame [clinicaltrials_vocabulary:time-frame]
PK samples will be collected a ...... ost-dose in each dosing period
description
Relative bioavailability of af ...... rved plasma concentration (Ct)
identifier
clinicaltrials_resource:4a03d7c7ec9a3bcf14a4ba6c22e2f0e1
title
Composite of plasma pharmacoki ...... ost-dose in each dosing period
@en
inDataset
type
label
Composite of plasma pharmacoki ...... 3d7c7ec9a3bcf14a4ba6c22e2f0e1]
@en